Study on the Safety and Effects of BMS-986507 Combinations in Adults with Advanced Solid Tumors
Sponsor: Bristol-Myers Squibb
Sponsor score: 60
ClinicalTrials ID:NCT06618287
This clinical trial is testing a new treatment called BMS-986507 in combination with other drugs to see if it is safe and how well it works in adults with advanced solid tumors.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The goal of this study is to find out if a new treatment, BMS-986507, when used with other medications, is safe and can be tolerated by adults with advanced solid tumors. Researchers will also measure how much of the drug is in the body and look for early signs of how well it might work against the cancer.
Eligibility Criteria
Inclusion Criteria
- Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
- Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- Participants must have a life expectancy of at least 3 months at the time of the first dose.
Exclusion Criteria
- Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
- Participants must not have any untreated symptomatic central nervous system (CNS) metastases.
- Participants must not have a history of serious recurrent infections.
- Participants must not have a history of severe heart disease.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Local Institution - 0009 | 33136 | Miami | Florida |
| John Theurer Cancer Center at Hackensack University Medical Center | 07601 | Hackensack | New Jersey |
| Local Institution - 0029 | 44195 | Cleveland | Ohio |
| Local Institution - 0014 | 15232 | Pittsburgh | Pennsylvania |
| Local Institution - 0012 | 98104 | Seattle | Washington |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.